EP0964853A1 - 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists - Google Patents

4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists

Info

Publication number
EP0964853A1
EP0964853A1 EP98903469A EP98903469A EP0964853A1 EP 0964853 A1 EP0964853 A1 EP 0964853A1 EP 98903469 A EP98903469 A EP 98903469A EP 98903469 A EP98903469 A EP 98903469A EP 0964853 A1 EP0964853 A1 EP 0964853A1
Authority
EP
European Patent Office
Prior art keywords
dihydro
alkyl
benzoimidazol
pharmaceutically acceptable
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98903469A
Other languages
German (de)
English (en)
French (fr)
Inventor
Richard Eric Mewshaw
James Albert Nelson
Uresh Shantilal Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP0964853A1 publication Critical patent/EP0964853A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to a series of 4-aminoalkoxy-l,3-dihydrobenzoimidazol-2- ones having dopaminergic properties and thus have utility in treating Parkinson's disease, Tourette's syndrome, schizophrenia, and alcohol and drug addiction.
  • the compounds of this invention are dopamine agonists having various degrees of intrinsic activity and are essentially free from extrapyramidal side effects. Some of the compounds are selective autoreceptor agonists, and therefore partial agonists (i.e. activate only autoreceptors versus postsynaptic D2 dopamine receptors). Efforts to induce antipsychotic activity with dopamine autoreceptor agonists have been successful (Dorsini et al., Adv. Biochem. PsychopharmacoL, 16, 645-648, 1977; Tamminga et al., Science, 200, 567-568; and Tamminga et al, Psychiatry, 398-402, 1986).
  • the invention compounds provide functional modulation of the dopamine systems of the brain without the excessive blockade of the postsynaptic dopamine receptors which have been observed to be responsible for the serious side effects frequently exhibited by agents found otherwise clinically effective for the treatment of schizophrenia.
  • Activation of the dopamine autoreceptors results in reduced neuronal firing a well as inhibition of dopamine synthesis and release and therefore provides a means of controlling hyperactivity of the dopaminergic systems.
  • the compounds of this invention were also found to have high intrinsic activity and therefore they can behave as the natural neurotransmitter, i.e., as full agonists. As such, they are useful in the treatment of diseases having abnormal concentrations of dopamine could be used as dopamine surrogates such as schizophrenia, Parkinson's disease and Tourette's syndrome. Such agents are partial agonists at the postsynaptic dopamine D2 receptor and are thereby useful in the treatment of alcohol and drug addiction.
  • Ciba-Geigy discloses compounds represented by the compound of the formula below which have both ⁇ and ⁇ -adrenergic properties and are useful as cardiovascular and antihypertensive agents.
  • R 1 is hydrogen or C ⁇ -C 6 alkyl
  • R 2 is selected from hydrogen, straight-chain and branched Ci-Cio alkyl, cyclohexylmethyl or -(CH 2 ) m Ar where Ar is phenyl, naphthyl, thienyl, furanyl or pyridinyl, each optionally substituted by one or two substituents selected independently from - alkyl, halogen, C,-C 6 alkoxide and trifluoromethyl; or NR ! R 2 is 1, 2, 3, 4-tetrahydroquinolin-l-yl or 1, 2, 3, 4-tetrahydroisoquinolin- 2-yl; m is 1-5; n is 1 or 2;
  • R 3 is hydrogen or C,-C 6 alkyl
  • Y is halogen, - alkyl, and - alkoxy
  • the pharmaceutically acceptable salts thereof can be formed with an invention compound and a pharmaceutically acceptable acid including, but not limited to, the hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, nitrate, acetate, fumarate, succinate, citrate, maleate, lactate, and benzoate salts.
  • the compounds of this invention are dopamine autoreceptor agonists, that is, they serve to modulate the synthesis and release of the neurotranmitter dopamine. They are thus useful for treatment of disorders of the dopaminergic system, such as schizophrenia, Parkinson's disease and Tourette's syndrome. Such agents are partial agonists at the postsynaptic dopamine D 2 receptor and are thereby useful in the treatment of alcohol and drug addiction.
  • the compounds of Formula I are generally prepared by the overall sequence depicted in Schemes I -IV.
  • R 1 and R 2 is hydrogen
  • Scheme I outlines a procedure to prepare an invention compound where R 3 is H.
  • Scheme II shows a synthetic route for invention compounds where R 3 is not H.
  • Scheme III shows a synthetic route for invention compounds where neither of R 1 and R 2 is H.
  • Scheme IV shows the procedure used to prepare an intermediate where Y is Cl.
  • the fumarate salt was prepared by adding a solution of the free base (165 mg) in warm isopropanol (15 mL) to an excess of fumaric acid in warm isopropanol (20 mL). Upon completion of addition crystals began forming and the mixture was allowed to cool to room temperature and the crystals filtered to afford 203 mg of fumarate salt, mp 201.5-202.5 °C; MS ESI m/e 298 (M+H + ).
  • Intrinsic activity is predicted using die ratio of the "low-affinity agonist" (LowAg) state of the receptor and the "high-affinity agonist” (HighAg) state of the receptor, i.e. LowAg/HighAg. These ratios correlate with the agonist, partial agonist, and antagonist activities of a given compound, which activities characterize a compounds ability to elicit an antipsychotic effect.
  • Affinity for the dopamine autoreceptor was established by a modification of the standard experimental test procedure of Seemen and Schaus, European Journal of Pharmacology 203: 105-109, 1991, wherein homogenized rat striatal brain tissue is incubated with 3 H-quinpirole (Quin.) and various concentrations of test compound, filtered and washed and counted in a Betaplate scintillation counter.
  • High affinity for the dopamine D-2 receptor was established by the standard experimental test procedure of Fields, et al., Brain Res., 136. 578 (1977) and Yamamura et al., eds., Neurotransmitter Receptor Binding, Raven Press, N.Y.
  • compositions of this invention may be administered neat or with a pharmaceutical carrier to a patient in need thereof.
  • the pharmaceutical carrier may be solid or liquid.
  • Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties n suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs.
  • the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
  • a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
  • the liquid carrier can contain other suitable pharmaceutical additives such a solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
  • liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferable sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil).
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be as either a liquid or a solid dosage form.
  • the compounds of this invention may be administered rectally in the form of a conventinal suppository.
  • the compounds of this invention may be formulated into an aqueous or partrially aqueous solution, which can then be utilized in die form of an aerosol.
  • the compounds of this invention may also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non-toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin.
  • the carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices.
  • the creams and ointments may be viscous liquid or semi-solid emulsions of either the oil in water or water in oil type.
  • Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable.
  • a variety of occlusive devices may be used to realease the active ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in d e literature.
  • the dosage to be used in the treatment of a specific patient suffering a dopamine imbalance must be subjectively determined by the attending physician.
  • the variables involved include the severity of the dysfunction, and the size, age, and response pattern of the patient.
  • the pharmaceutical composition is in unit dosage form, e.g., as tablets or capsules.
  • the composition is sub-divided in unit dose containing appropriate quantities of die active ingredient;
  • the unit dosage form can be packaged compositions, for example packed powders, vials, ampoules, prefilled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP98903469A 1997-02-18 1998-01-13 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists Withdrawn EP0964853A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80187097A 1997-02-18 1997-02-18
PCT/US1998/000623 WO1998035946A1 (en) 1997-02-18 1998-01-13 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists
US801870 2004-03-16

Publications (1)

Publication Number Publication Date
EP0964853A1 true EP0964853A1 (en) 1999-12-22

Family

ID=25182225

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98903469A Withdrawn EP0964853A1 (en) 1997-02-18 1998-01-13 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists

Country Status (14)

Country Link
EP (1) EP0964853A1 (pt)
JP (1) JP2001511804A (pt)
KR (1) KR20000071160A (pt)
CN (1) CN1138761C (pt)
AR (1) AR011138A1 (pt)
AU (1) AU744443B2 (pt)
BR (1) BR9807703A (pt)
CA (1) CA2278747A1 (pt)
HU (1) HUP0001262A3 (pt)
IL (1) IL131156A0 (pt)
NZ (1) NZ337271A (pt)
TW (1) TW383303B (pt)
WO (1) WO1998035946A1 (pt)
ZA (1) ZA981310B (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
GB9210632D0 (en) * 1992-05-19 1992-07-01 Fisons Plc Compounds
SI0707007T1 (en) * 1994-10-14 2002-04-30 Merck Patent Gmbh (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent
AR004523A1 (es) * 1995-11-06 1998-12-16 American Home Prod 2-(AMINOMETIL)-3,4,7,9-TETRAHIDRO-2H-PIRANO-[2,3e] INDOL-8-ONAS Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
AU4091797A (en) * 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy-indolone derivatives as dopamine d2 agonists
EP0923551B1 (en) * 1996-08-27 2002-06-05 American Home Products Corporation 4-aminoethoxy indolone derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9835946A1 *

Also Published As

Publication number Publication date
ZA981310B (en) 1999-08-17
JP2001511804A (ja) 2001-08-14
NZ337271A (en) 2001-01-26
CN1252060A (zh) 2000-05-03
TW383303B (en) 2000-03-01
AR011138A1 (es) 2000-08-02
HUP0001262A3 (en) 2002-04-29
CA2278747A1 (en) 1998-08-20
BR9807703A (pt) 2000-05-02
WO1998035946A1 (en) 1998-08-20
AU6023498A (en) 1998-09-08
AU744443B2 (en) 2002-02-21
HUP0001262A2 (hu) 2001-04-28
IL131156A0 (en) 2001-01-28
KR20000071160A (ko) 2000-11-25
CN1138761C (zh) 2004-02-18

Similar Documents

Publication Publication Date Title
JP2005505530A (ja) アミノアルキル置換芳香族二環式化合物、それらの製造方法及び医薬としてのそれらの使用
IE66112B1 (en) Piperidinyl benzimidazoles as antihistamines
EP3584237B1 (en) Alpha adrenergic receptor modulators
EP0923551B1 (en) 4-aminoethoxy indolone derivatives
US6103744A (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one dopamine autoreceptor agonists
US5486517A (en) Benzimidazoles and imidazopyridines as central nervous system agents
EP0964853A1 (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists
US6127380A (en) 4-aminoalkoxy-1H-benzoimidazoles
AU5915398A (en) 4-aminoalkoxy-1H-benzimidazole derivatives, their preparation and their use as dopamine autoreceptor (D2) agonists
US5972958A (en) 4-aminoalkoxy-1,3-dihydro-benzoimidazol-2-thiones
US5756521A (en) Chroman-2-ylmethylamino derivatives
MXPA99007585A (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, theirpreparation and their use as dopamine autoreceptor (d2) agonists
EP1073636A1 (en) 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
WO1998035947A1 (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-thiones derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists
AU722616B2 (en) 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
US5922715A (en) 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
EP0923576B1 (en) 4-aminoethoxy-indolone derivatives as dopamine d2 agonists
MXPA99007586A (en) 4-aminoalkoxy-1h-benzimidazole derivatives, their preparation and their use as dopamine autoreceptor (d2
MXPA99007587A (en) 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-thiones derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists
FR2489822A1 (fr) Derives de l'imidazole, leur preparation et leurs utilisations therapeutiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990810

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990810;LT PAYMENT 19990810;LV PAYMENT 19990810;MK PAYMENT 19990810;RO PAYMENT 19990810;SI PAYMENT 19990810

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH

17Q First examination report despatched

Effective date: 20030207

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041221

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1024233

Country of ref document: HK